World Tuberculosis Day 2024 theme “Yes! We can end TB” can be made a reality through concerted global efforts that advance detection, diagnosis, and treatment of tuberculosis infection and disease

Goletti, Delia; Al-Abri, Seif; Migliori, Giovanni Battista; Arlehamn, Cecilia Lindestam; Haldar, Pranabashis; Sundling, Christopher; da Costa, Christopher; To, Kin Wang; Martineau, Adrian R.; Petersen, Eskild; Zumla, Alimuddin; Shan Lee, Shui

doi:10.1016/j.ijid.2024.106993

Cited by 8 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 2 , 9 , 22 , 71–74 Therefore, countries must ensure they implement several solutions to address TB including developing new diagnostic tests, increasing investments to accelerate the development of the potential new TB vaccines in the pipeline, increasing TB awareness, promoting adherence to anti-TB drugs, implementing new immune strategies for better vaccine design, develop good quality anti-TB drugs, new therapies, implementation of prevention through screening using standardized old and new diagnostic tests for TB infection detection. 75–78 …”

Section: Discussionmentioning

confidence: 99%

Drug resistance profiles of Mycobacterium tuberculosis clinical isolates by genotype MTBDRplus line probe assay in Zambia: findings and implications

Kangongwe,

Mwanza,

Mwamba

et al. 2024

JAC-Antimicrobial Resistance

View full text Add to dashboard Cite

Background The emergence of drug resistance is a threat to global tuberculosis (TB) elimination goals. This study investigated the drug resistance profiles of Mycobacterium tuberculosis (M. tuberculosis) using the Genotype MTBDRplus Line Probe Assay at the National Tuberculosis Reference Laboratory (NTRL) in Zambia. Methods A cross-sectional study was conducted between January 2019 and December 2020. GenoType MTBDRplus line probe assay records for patients at the NTRL were reviewed to investigate drug susceptibility profiles of M. tuberculosis isolates to rifampicin and isoniazid. Data analysis was done using Stata version 16.1. Results Of the 241 patient records reviewed, 77% were for females. Overall, 44% of patients were newly diagnosed with TB, 29% had TB relapse, 10% treatment after failure and 8.3% treatment after loss to follow-up. This study found that 65% of M. tuberculosis isolates were susceptible to rifampicin and isoniazid. Consequently, 35% of the isolates were resistant to rifampicin and/or isoniazid and 21.2% were multidrug-resistant (MDR). Treatment after failure [relative risk ratios (RRR) = 6.1, 95% CI: 1.691–22.011] and treatment after loss to follow-up (RRR = 7.115, 95% CI: 1.995–25.378) were significantly associated with MDR-TB. Unknown HIV status was significantly associated with isoniazid mono-resistance (RRR = 5.449, 95% CI: 1.054–28.184). Conclusions This study found that 65% of M. tuberculosis isolates were susceptible to rifampicin and isoniazid while 35% were resistant. Consequently, a high prevalence of MDR-TB is of public health concern. There is a need to heighten laboratory surveillance and early detection of drug-resistant TB to prevent the associated morbidity and mortality.

show abstract

Section: Discussionmentioning

confidence: 99%

Drug resistance profiles of Mycobacterium tuberculosis clinical isolates by genotype MTBDRplus line probe assay in Zambia: findings and implications

Kangongwe,

Mwanza,

Mwamba

et al. 2024

JAC-Antimicrobial Resistance

View full text Add to dashboard Cite

show abstract

“…6 Yadav / IP Indian Journal of Immunology and Respiratory Medicine 2024;9(1):47-48 Furthermore, the theme of World TB Day 2024 offers optimism that strong leadership, more funding, and quicker adoption of new WHO guidelines might get things back on track to stop the tuberculosis epidemic. 9 Also, there is an increased effort to prevent the progression of the latent infection to active tuberculosis by timely administration of tuberculosis preventive treatment, even in contacts with drug-resistant patients. 10 This is based on the fact that individuals infected with tuberculosis (or latent tuberculosis) have a lifetime risk of 5-10% of acquiring tuberculosis disease.…”

Section: Perspectivementioning

confidence: 99%

\'Yes! We can end TB’ the theme of the world tuberculosis day 2024: A commitment to fight the oldest known infectious disease from the world

Yadav

2024

IJIRM

View full text Add to dashboard Cite

Tuberculosis is a constant issue related to public health. The disease is highly infectious, and about one-fourth of the global population is presumed to be infected. The efforts for tuberculosis control are in full swing, especially in the endemic countries. The World Tuberculosis Day was celebrated on March 24, 2024; however, the theme of the last year, i.e., 'Yes! We can end TB', was continued for 2024. The theme justifies the commitment of stakeholders and policymakers to a sustained effort to eliminate tuberculosis.

show abstract

Clinical insights into tuberculosis otitis media: diagnosis, treatment, and management outcomes

Peng,

Chen,

et al. 2024

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

World Tuberculosis Day 2024 theme “Yes! We can end TB” can be made a reality through concerted global efforts that advance detection, diagnosis, and treatment of tuberculosis infection and disease

Cited by 8 publications

References 22 publications

Drug resistance profiles of Mycobacterium tuberculosis clinical isolates by genotype MTBDRplus line probe assay in Zambia: findings and implications

Drug resistance profiles of Mycobacterium tuberculosis clinical isolates by genotype MTBDRplus line probe assay in Zambia: findings and implications

\'Yes! We can end TB’ the theme of the world tuberculosis day 2024: A commitment to fight the oldest known infectious disease from the world

Clinical insights into tuberculosis otitis media: diagnosis, treatment, and management outcomes

Contact Info

Product

Resources

About